Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

129.89USD
21 Feb 2017
Change (% chg)

-- (--)
Prev Close
$129.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
861,459
52-wk High
$161.86
52-wk Low
$109.12

ALXN.OQ

Chart for ALXN.OQ

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $29,175.08
Shares Outstanding(Mil.): 224.61
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): 73.81 28.39 29.32
EPS (TTM): 1.76 -- --
ROI: 3.22 13.54 13.03
ROE: 4.71 14.43 14.17

UPDATE 3-Alexion Pharma's revenue forecast allays investor fears

* 2017 rev forecast just under estimates, but reassuring-analysts

Feb 16 2017

BRIEF-Alexion interim CEO says looking for opportunities in M&A front

* Alexion CFO says "we're preparing for potential tax reform": conf call

Feb 16 2017

Alexion Pharma revenue forecast allays fears about Soliris' future

Alexion Pharmaceuticals Inc forecast 2017 revenue that will likely quell investor concerns, as the drugmaker looks to steady the ship following the recent exits of its chief executive and chief financial officer.

Feb 16 2017

BRIEF-Alexion Pharmaceuticals posts Q4 adj. earnings $1.26/shr

* Alexion reports fourth quarter and full year 2016 results and provides financial guidance for 2017

Feb 16 2017

Alexion Pharma's revenue rises 18.5 pct

Feb 16 Alexion Pharmaceuticals Inc reported an 18.5 percent rise in fourth-quarter revenue, helped by demand for its costly rare blood disorder drug Soliris.

Feb 16 2017

BRIEF-Alexion interim CEO says company is not up for sale - conf

* Alexion interim CEO says they are not up for sale - JPM Healthcare conf

Jan 09 2017

BRIEF-Alexion submits U.S. and EU applications seeking approval of Soliris as a treatment for patients with refractory generalized myasthenia gravis

* Alexion submits U.S. and EU applications seeking approval of Soliris (eculizumab) as a treatment for patients with refractory generalized myasthenia gravis (gMG)

Jan 09 2017

BRIEF-FDA grants orphan drug designation to ALXN1210

* FDA grants orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (pnh)

Jan 06 2017

Alexion says no need to revise earnings, shares rise

Alexion Pharmaceuticals Inc on Wednesday filed its delayed third-quarter 2016 financial report with U.S. regulators and said an investigation into allegations regarding sales practices found no need to restate previous financial results.

Jan 04 2017

Alexion Pharmaceuticals says CEO, CFO resign, shares slump

Alexion Pharmaceuticals Inc's chief executive officer and chief financial officer resigned, a month after the drugmaker said it was investigating allegations related to sales practices of its flagship drug.

Dec 12 2016

More From Around the Web

Competitors

Earnings vs. Estimates